A path of effort to make a healthy life and a happy society
Jeonbuk Technopark-PDIGID-Repure Life Science, signed MOU to activate agricultural & Bio industry
Cambridge Milner Institute – Yonsei University
※ New research target discovery progress on AI-based refractory tumor
Cleveland Clinic AI Drug Development & Big Data Joint Research Agreement
Started development of immune anticancer drugs (3rd and 4th generation) -1st June 2019
※ ‘Repure Life Science-KBIO Health Immune Cancer Development (3rd and 4th Generation) - 1st June 2019: Signed New Drug Development Center Contract
Joint research business agreement with Cambridge Milner Institute AI drug development
Selected and moved to Osong New Drug Research Laboratory
Joint research development and patent technology transfer contract related to immune anticancer drug
※ Yonsei University/Health System – Asan Medical Center – University of Ulsan– NKMAX– Repure Life Science Inc.
Establishment of Research Institute
Change of company name (Repure Bio INC. → Repure Life Science INC.)
Signed MOU with 'Repure Bio - Sookmyung Women's University Research & Business Development Foundation'
Consultation on technology transfer of new materials for brain cancer
Signed MOU with 'Repure Bio - Duksung Innovative Drug Center'
Joint research and development related to metabolic anticancer drugs and Signed the technology transfer agreement with priority of metabolic anticancer drugs
'Yonsei University - Repure Bio' [Application No. 10-2017-0111840]
Establishment of corporation (Repure Bio INC.)
Selected and Participated in 'Yonsei Enterprise Support Foundation'